Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Incorporating thyroid markers in Down syndrome screening protocols

I. Dhaifalah, T. Salek, D. Langova, H. Cuckle,

. 2017 ; 37 (5) : 510-514. [pub] 20170424

Language English Country Great Britain

Document type Evaluation Study, Journal Article

Persistent link   https://www.medvik.cz/link/bmc18010703

OBJECTIVE: The article aimed to assess the benefit of incorporating maternal serum thyroid disease marker levels (thyroid-stimulating hormone and free thyroxine) into first trimester Down syndrome screening protocols. METHODS: Statistical modelling was used to predict performance with and without the thyroid markers. Two protocols were considered: the combined test and the contingent cell-free DNA (cfDNA) test, where 15-40% women are selected for cfDNA because of increased risk based on combined test results. Published parameters were used for the combined test, cfDNA and the Down syndrome means for thyroid-stimulating hormone and free thyroxine; other parameters were derived from a series of 5230 women screened for both thyroid disease and Down syndrome. RESULTS: Combined test: For a fixed 85% detection rate, the predicted false positive rate was reduced from 5.3% to 3.6% with the addition of the thyroid markers. Contingent cfDNA test: For a fixed 95% detection rate, the proportion of women selected for cfDNA was reduced from 25.6% to 20.2%. CONCLUSIONS: When screening simultaneously for maternal thyroid disease and Down syndrome, thyroid marker levels should be used in the calculation of Down syndrome risk. The benefit is modest but can be achieved with no additional cost. © 2017 John Wiley & Sons, Ltd.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010703
003      
CZ-PrNML
005      
20180416142159.0
007      
ta
008      
180404s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pd.5047 $2 doi
035    __
$a (PubMed)28374559
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Dhaifalah, Ishraq $u Department of Obstetrics and Gynecology, Tomas Bata Regional Hospital, Zlin, Czech Republic. Center of Fetal Medicine and Medical Genetics (FETMED), Czech Republic.
245    10
$a Incorporating thyroid markers in Down syndrome screening protocols / $c I. Dhaifalah, T. Salek, D. Langova, H. Cuckle,
520    9_
$a OBJECTIVE: The article aimed to assess the benefit of incorporating maternal serum thyroid disease marker levels (thyroid-stimulating hormone and free thyroxine) into first trimester Down syndrome screening protocols. METHODS: Statistical modelling was used to predict performance with and without the thyroid markers. Two protocols were considered: the combined test and the contingent cell-free DNA (cfDNA) test, where 15-40% women are selected for cfDNA because of increased risk based on combined test results. Published parameters were used for the combined test, cfDNA and the Down syndrome means for thyroid-stimulating hormone and free thyroxine; other parameters were derived from a series of 5230 women screened for both thyroid disease and Down syndrome. RESULTS: Combined test: For a fixed 85% detection rate, the predicted false positive rate was reduced from 5.3% to 3.6% with the addition of the thyroid markers. Contingent cfDNA test: For a fixed 95% detection rate, the proportion of women selected for cfDNA was reduced from 25.6% to 20.2%. CONCLUSIONS: When screening simultaneously for maternal thyroid disease and Down syndrome, thyroid marker levels should be used in the calculation of Down syndrome risk. The benefit is modest but can be achieved with no additional cost. © 2017 John Wiley & Sons, Ltd.
650    _2
$a dospělí $7 D000328
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a volné cirkulující nukleové kyseliny $x analýza $x krev $7 D000073888
650    _2
$a Downův syndrom $x krev $x komplikace $x diagnóza $x patofyziologie $7 D004314
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a plošný screening $x metody $7 D008403
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a těhotenství $7 D011247
650    _2
$a první trimestr těhotenství $x krev $7 D011261
650    _2
$a prenatální diagnóza $x metody $7 D011296
650    _2
$a senzitivita a specificita $7 D012680
650    _2
$a nemoci štítné žlázy $x krev $x diagnóza $7 D013959
650    _2
$a testy funkce štítné žlázy $x metody $7 D013960
650    _2
$a štítná žláza $x patofyziologie $7 D013961
650    _2
$a thyreotropin $x analýza $x krev $7 D013972
650    _2
$a thyroxin $x analýza $x krev $7 D013974
655    _2
$a hodnotící studie $7 D023362
655    _2
$a časopisecké články $7 D016428
700    1_
$a Salek, Tomas $u Department of Clinical Biochemistry, Tomas Bata Regional Hospital, Zlin, Czech Republic.
700    1_
$a Langova, Dagmar $u Department of Internal Medicine Clinic, Tomas Bata Regional Hospital, Zlin, Czech Republic.
700    1_
$a Cuckle, Howard $u Department of Obstetrics and Gynaecology, Columbia University Medical Centre, New York, NY, USA.
773    0_
$w MED00003882 $t Prenatal diagnosis $x 1097-0223 $g Roč. 37, č. 5 (2017), s. 510-514
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28374559 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180416142256 $b ABA008
999    __
$a ok $b bmc $g 1288188 $s 1007515
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 37 $c 5 $d 510-514 $e 20170424 $i 1097-0223 $m Prenatal diagnosis $n Prenat Diagn $x MED00003882
LZP    __
$a Pubmed-20180404
Back

Find record

Citation metrics

Archiving options